title: DEA reschedules hydrocodone combination products.
authors: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, U.S.A. jpjmd@msn.com.
authors: Joseph V
authors: JV
authors: Pergolizzi
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D001294:Attitude to Health; D004338:Drug Combinations; D004335:Drug and Narcotic Control; D006801:Humans; D006853:Hydrocodone / Q000627:therapeutic use*; D064086:Medical Marijuana / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000517:prevention & control*; D010146:Pain / Q000188:drug therapy*; D059408:Pain Management; D014481:United States
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid; D004338:Drug Combinations; D064086:Medical Marijuana; D000082:Acetaminophen; D006853:Hydrocodone